SAN DIEGO, Feb. 1 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) announced that it has completed its $5.3 million registered direct offering with institutional and other accredited or qualified investors that was previously announced on January 31, 2008. Empire Asset Management Company acted as the sole placement agent for the transaction.
The securities were offered pursuant to an effective shelf registration statement filed by Cardium with the U.S. Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy, and these securities may not be sold in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies,
Inc. and the Tissue Repair Company, are medical technology companies
primarily focused on the development, manufacture and sale of innovative
therapeutic products and devices for cardiovascular, ischemic and related
indications. Cardium's lead product candidate, Generx(TM) (alferminogene
tadenovec, Ad5FGF-4), is a DNA-based growth factor therapeutic being
developed for potential use by interventional cardiologists as a one-time
treatment to promote and stimulate the growth of collateral circulation in
the hearts of patients with ischemic conditions such as recurrent angina.
For more information about Cardium Therapeutics and its businesses,
products and therapeutic candidates, please visit http://www.cardiumthx.com
or view its 2006 Annual Report at
|SOURCE Cardium Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved